The landscape of tobacco use in the United States is at a pivotal juncture, marked by two contrasting trends: youth tobacco use has plummeted to historic lows, while adult cigarette smoking stubbornly persists as the leading cause of preventable death. This dichotomy underscores the need for a nuanced public health approach that simultaneously protects young people and empowers adult smokers with better options.
Recent data from the 2025 National Youth Tobacco Survey reveal a significant decline in youth tobacco use across all categories between 2022 and 2025. Current use of tobacco products, combustible products, and e-cigarettes all saw marked reductions. Notably, nicotine pouch use among youth remained low and stable at 1.7% in 2025, virtually unchanged from 1.8% in 2024. These figures reflect years of concerted efforts in prevention, age restrictions, and public education, and they counter the prevailing narrative that youth vaping and nicotine use are spiraling out of control.
However, the public health community cannot afford complacency. The Centers for Disease Control and Prevention (CDC) continues to highlight that cigarette smoking remains the leading cause of preventable death in the U.S., with millions of adults still smoking despite decades of warnings and cessation efforts. While quitting entirely is always the optimal outcome, for those who cannot or will not quit, harm reduction strategies become essential.
In this context, the U.S. Food and Drug Administration's (FDA) recent decision regarding ZYN nicotine pouches marks a watershed moment. After rigorous scientific review, the FDA issued modified risk orders for 20 ZYN products, permitting them to be marketed with the claim: "Using ZYN instead of cigarettes puts adults at lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." This authorization does not imply these products are safe, nor does it encourage non-smokers or youth to use them. Rather, it provides adult smokers with accurate, science-based information about relative risks, enabling them to make informed decisions.
The significance of this action lies in its recognition that not all nicotine products pose equal risks. Cigarettes, which involve combustion, expose users to thousands of harmful chemicals, whereas smoke-free nicotine products like ZYN deliver nicotine without combustion and significantly lower levels of toxicants. By authorizing a modified risk claim, the FDA acknowledges this distinction within a stringent regulatory framework.
Importantly, this progress has not compromised youth prevention efforts. PMI U.S., the company behind ZYN, has implemented a responsible marketing approach that includes age-gated websites requiring independent age verification for those 21 and older, advertising featuring only individuals aged 35 or older, and a prohibition on social media influencer endorsements and product placement in movies or TV shows. These measures are part of a comprehensive 10-point underage prevention plan that supports retail monitoring, enforcement against illicit products, and compliance checks, including FDA mystery shopping.
The dual imperatives of preventing youth initiation and supporting adult smokers in transitioning to lower-risk alternatives are not mutually exclusive. The current data provide compelling evidence that these goals can be achieved simultaneously. As Dr. Matthew Holman, vice president and chief science and regulatory strategy officer for PMI U.S. and former chief scientist at FDA's Center for Tobacco Products, notes, "The United States has made extraordinary progress reducing youth tobacco use. That is worth saying plainly, and it is worth protecting. The next step is to bring the same seriousness to the adults who still smoke."
With continued vigilance from regulators, industry, and public health advocates, a mature tobacco policy can indeed do both: keep young people from starting and offer adults who smoke a better choice.
